⌘K
Loading ticker…
As of 2026-08-24, Imax Corp (IMAX) has a 3-month relative strength percentile of 91 and a leadership percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 68. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.0%, relative volume 0.98×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
IMAX is in a stage 2 uptrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 22.0% / 40.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
IMAX is held by 9 ETFs as of May 2026. Top owner: AVUV at 0.06% weight, $17M notional. Top 3 carry $22M.
Held by 12 ETFs · $24M across latest filings · largest weight 0.24% (MMSC).
Top 9 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | 0.06% | $17M | −0.04 pp |
| AVSC | 0.15% | $4M | −0.04 pp |
| AVUSAvantis U.S. Equity ETF | 0.01% | $1M | — |
| GSSC | 0.06% | $577K | −0.01 pp |
| MMSC | 0.24% | $128K | new |
| AVSU | 0.02% | $71K | — |
| AVUQ | 0.03% | $70K | −0.01 pp |
| AVTM | 0.00% | $37K | — |
| EBI | 0.00% | $11K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMAX Jan avg: -1.15% median: -6.27% win: 25% σ: 11.45% n: 4 2022-04-12 → 2026-07-31 | IMAX Feb avg: 15.62% median: 15.66% win: 100% σ: 8.12% n: 4 2022-04-12 → 2026-07-31 | IMAX Mar avg: -2.48% median: -1.34% win: 50% σ: 7.26% n: 4 2022-04-12 → 2026-07-31 | IMAX Apr avg: -1.02% median: -0.99% win: 40% σ: 6.57% n: 5 2022-04-12 → 2026-07-31 | IMAX May avg: 2.75% median: 4.37% win: 80% σ: 12.09% n: 5 2022-04-12 → 2026-07-31 | IMAX Jun avg: -0.33% median: 0.40% win: 60% σ: 1.88% n: 5 2022-04-12 → 2026-07-31 | IMAX Jul avg: 9.19% median: 8.36% win: 60% σ: 13.92% n: 5 2022-04-12 → 2026-07-31 | IMAX Aug avg: 2.09% median: 2.17% win: 75% σ: 7.27% n: 4 2022-04-12 → 2026-07-31 (current) | IMAX Sep avg: 0.63% median: -1.11% win: 50% σ: 10.39% n: 4 2022-04-12 → 2026-07-31 | IMAX Oct avg: 0.52% median: -3.27% win: 25% σ: 12.53% n: 4 2022-04-12 → 2026-07-31 | IMAX Nov avg: 10.69% median: 11.25% win: 75% σ: 18.57% n: 4 2022-04-12 → 2026-07-31 | IMAX Dec avg: -5.54% median: -4.28% win: 0% σ: 5.58% n: 4 2022-04-12 → 2026-07-31 |